ResurFX™ Fractional Non-Ablative Laser Module to be Unveiled by Lumenis® at the American Academy of Dermatology’s Annual Meeting

- Expands Use of Gold-Standard M22 Device in a Broader Range of Common Skin Disorders including Acne Scars, Surgical Scars and Stretch Marks -

- Company to host educational symposium and practice-building seminars at AAD, demonstrating commitment to innovation and patient care -

YOKNEAM, Israel (March 2, 2013) – At the 71st Annual Meeting of the American Academy of Dermatology (AAD), the ResurFX* module will be launched for international sales by Lumenis Ltd., the world's largest developer and manufacturer of advanced medical lasers for aesthetic, surgical, and ophthalmic applications.  ResurFX is an affordable module for the M22TM device, the company’s multi-application, multi-technology platform.  The 1565nm fiber laser energy is delivered by patent-pending CoolScanTM scanner to perform non-sequential scanning to maximize efficacy and reproducible results.  The module extends the ability of Lumenis’ gold-standard M22 to perform non-ablative skin resurfacing and treat some of the most common aesthetic skin concerns including acne and surgical scars, skin discoloration, periorbital wrinkles and stretch marks.  Although the ResurFX module has not yet been FDA cleared, international physicians may see it on display along with Lumenis’ broad portfolio of medical lasers for body shaping, tattoo removal, hair removal, scar revision and IPL skin rejuvenation at booth #2035 throughout the AAD meeting, which runs from March 1 to 5 in Miami Beach.

“The new ResurFX module for M22 is a true non-ablative fractional fiber laser technology. It uses a unique algorithm to apply micro-beams of 1565nm laser energy in a non-sequential pattern to increase patient comfort and minimize non-specific thermal damage using the ‘cool-scanning’ technology pioneered by Lumenis. With over 600 parameter combinations, ResurFX gives me the greatest possible flexibility in treating a wide range of conditions," said Dr. Mitchel P. Goldman, MD, principle investigator for ResurFX, Volunteer Clinical Professor of Dermatology, University of California, San Diego and Medical Director, Dermatology/Cosmetic Laser Associates of La Jolla, Inc.

"Lumenis invented, advanced, and perfected Intense Pulsed Light (IPL) technology with both doctors and patients in mind, and we are committed to remaining at the forefront of innovation so that we can solidify our 45 year legacy as the partner of choice in medical devices,” said Roy Ramati, Vice President & General Manager of the Aesthetic Strategic Business Unit at Lumenis. “We work with a broad network of leading physicians worldwide

to develop practical solutions to help our customers meet the real-world needs of their patients. The M22 is the only multi-application, multi-technology platform that combines three proprietary, robust technologies offering more than 40 indications for use in one platform: Intense Pulsed Light with Optimal Pulse Technology™, Multi-spot Nd:YAG and now ResurFX for a complete aesthetic workstation.”

Lumenis will also have a variety of educational events taking place at its booth throughout the AAD conference.

Lumenis at the AAD 2013

Educational Activities at Booth #2035
Date Time Topic Speaker:

Lumenis will also host a Clinical Symposium entitled “Versatility Drives Patient and Practice Outcomes” on March 2 at 7pm at the Hilton Bentley South Beach, 101 Ocean Drive, Miami Beach. The content will focus on how dermatology practices can be transformed via UltraPulse® SCAAR FX™, M22 with ResurFX™ module, QX Max and VaserShape®. The session will feature presentations and panel discussions with Mitch Goldman, M.D., Mark Taylor, M.D., Jill Waibel, M.D. and Michael Gold, M.D. 

To celebrate the company’s 45-year partnership with the physician community and sales of over 80,000 medical lasers, Lumenis will also host celebrations at its booth for the final hour of the exhibit schedule on March 2 and 3.

About Lumenis

Lumenis, the world's largest medical laser company, is a global developer, manufacturer and distributor of laser and light-based devices for surgical, aesthetic and ophthalmic applications, with more than 900 employees worldwide. Lumenis has 265 registered patents, over 260 FDA clearances, an installed base of over 80,000 systems and a presence in over 80 countries. Lumenis endeavors to bring the finest state of the art technology products to the market, fulfilling the highest standards of excellence, quality and reliability, delivering premium value and service to its customers. The name Lumenis is derived from the Latin words meaning “Light of Life” highlighting the light - the basis of our technologies - used to enhance life.

For more information about Lumenis and its products, please visit: www.lumenis.com.

CoolScanTM, Optimal Pulse Technology™, ResurFX™, UltraPulse®, SCAAR FX™, Lumenis® and the Lumenis logo are trademarks or registered trademarks of Lumenis, Ltd.

VaserShape® is a registered trademark of Sound Surgical Technologies, LLC.

*The ResurFX module of M22 is available in the U.S. pending U.S. Food and Drug Administration (FDA) clearance.